nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—migraine—Acetylsalicylic acid—coronary artery disease	0.405	1	CpDpCtD
Dihydroergotamine—HTR1B—Penbutolol—coronary artery disease	0.0648	0.177	CbGbCtD
Dihydroergotamine—HTR1A—Penbutolol—coronary artery disease	0.0406	0.111	CbGbCtD
Dihydroergotamine—ABCB1—Ticagrelor—coronary artery disease	0.0222	0.0606	CbGbCtD
Dihydroergotamine—ABCB1—Clopidogrel—coronary artery disease	0.0137	0.0374	CbGbCtD
Dihydroergotamine—ABCB1—Perindopril—coronary artery disease	0.0137	0.0374	CbGbCtD
Dihydroergotamine—CYP3A4—Ticagrelor—coronary artery disease	0.0133	0.0363	CbGbCtD
Dihydroergotamine—ABCB1—Telmisartan—coronary artery disease	0.012	0.0327	CbGbCtD
Dihydroergotamine—ABCB1—Pitavastatin—coronary artery disease	0.012	0.0327	CbGbCtD
Dihydroergotamine—CYP3A4—Fenofibrate—coronary artery disease	0.0118	0.0323	CbGbCtD
Dihydroergotamine—ABCB1—Enalapril—coronary artery disease	0.0114	0.031	CbGbCtD
Dihydroergotamine—ABCB1—Lisinopril—coronary artery disease	0.0114	0.031	CbGbCtD
Dihydroergotamine—ABCB1—Timolol—coronary artery disease	0.00966	0.0264	CbGbCtD
Dihydroergotamine—CYP3A4—Gemfibrozil—coronary artery disease	0.00947	0.0259	CbGbCtD
Dihydroergotamine—ABCB1—Ezetimibe—coronary artery disease	0.00883	0.0241	CbGbCtD
Dihydroergotamine—ABCB1—Acetylsalicylic acid—coronary artery disease	0.00861	0.0235	CbGbCtD
Dihydroergotamine—ABCB1—Captopril—coronary artery disease	0.0085	0.0232	CbGbCtD
Dihydroergotamine—CYP3A4—Clopidogrel—coronary artery disease	0.00821	0.0224	CbGbCtD
Dihydroergotamine—ABCB1—Simvastatin—coronary artery disease	0.00821	0.0224	CbGbCtD
Dihydroergotamine—ABCB1—Lovastatin—coronary artery disease	0.00803	0.0219	CbGbCtD
Dihydroergotamine—ABCB1—Pravastatin—coronary artery disease	0.00803	0.0219	CbGbCtD
Dihydroergotamine—CYP3A4—Eplerenone—coronary artery disease	0.00763	0.0208	CbGbCtD
Dihydroergotamine—ABCB1—Atorvastatin—coronary artery disease	0.00732	0.02	CbGbCtD
Dihydroergotamine—CYP3A4—Enalapril—coronary artery disease	0.0068	0.0186	CbGbCtD
Dihydroergotamine—ABCB1—Losartan—coronary artery disease	0.00669	0.0183	CbGbCtD
Dihydroergotamine—HTR2B—cardial valve—coronary artery disease	0.00648	0.556	CbGeAlD
Dihydroergotamine—CYP3A4—Ezetimibe—coronary artery disease	0.00529	0.0144	CbGbCtD
Dihydroergotamine—CYP3A4—Rosuvastatin—coronary artery disease	0.00529	0.0144	CbGbCtD
Dihydroergotamine—CYP3A4—Simvastatin—coronary artery disease	0.00492	0.0134	CbGbCtD
Dihydroergotamine—CYP3A4—Pravastatin—coronary artery disease	0.00481	0.0131	CbGbCtD
Dihydroergotamine—CYP3A4—Lovastatin—coronary artery disease	0.00481	0.0131	CbGbCtD
Dihydroergotamine—CYP3A4—Atorvastatin—coronary artery disease	0.00438	0.012	CbGbCtD
Dihydroergotamine—CYP3A4—Losartan—coronary artery disease	0.00401	0.0109	CbGbCtD
Dihydroergotamine—HTR1B—artery—coronary artery disease	0.00108	0.0926	CbGeAlD
Dihydroergotamine—HTR1D—artery—coronary artery disease	0.00104	0.0896	CbGeAlD
Dihydroergotamine—Bromocriptine—HTR7—coronary artery disease	0.000403	0.347	CrCbGaD
Dihydroergotamine—HTR1B—cardiovascular system—coronary artery disease	0.000375	0.0322	CbGeAlD
Dihydroergotamine—HTR1D—cardiovascular system—coronary artery disease	0.000363	0.0311	CbGeAlD
Dihydroergotamine—HTR2B—heart—coronary artery disease	0.000358	0.0307	CbGeAlD
Dihydroergotamine—Bromocriptine—ADRB1—coronary artery disease	0.000345	0.297	CrCbGaD
Dihydroergotamine—HTR2B—cardiovascular system—coronary artery disease	0.000338	0.029	CbGeAlD
Dihydroergotamine—HTR1A—cardiovascular system—coronary artery disease	0.000303	0.026	CbGeAlD
Dihydroergotamine—HTR2B—blood—coronary artery disease	0.000267	0.0229	CbGeAlD
Dihydroergotamine—ADRA2A—heart—coronary artery disease	0.000225	0.0193	CbGeAlD
Dihydroergotamine—Ergotamine—HTR2A—coronary artery disease	0.00021	0.181	CrCbGaD
Dihydroergotamine—Bromocriptine—HTR2A—coronary artery disease	0.000203	0.175	CrCbGaD
Dihydroergotamine—ADRA2A—cardiac atrium—coronary artery disease	0.000192	0.0165	CbGeAlD
Dihydroergotamine—ADRA2A—blood—coronary artery disease	0.000168	0.0144	CbGeAlD
Dihydroergotamine—CYP3A4—blood—coronary artery disease	0.000132	0.0113	CbGeAlD
Dihydroergotamine—ABCB1—heart—coronary artery disease	0.000125	0.0107	CbGeAlD
Dihydroergotamine—ABCB1—cardiovascular system—coronary artery disease	0.000118	0.0101	CbGeAlD
Dihydroergotamine—ABCB1—blood—coronary artery disease	9.35e-05	0.00802	CbGeAlD
Dihydroergotamine—Dermatitis—Lovastatin—coronary artery disease	6.73e-05	0.000481	CcSEcCtD
Dihydroergotamine—Dyspepsia—Losartan—coronary artery disease	6.71e-05	0.00048	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Perindopril—coronary artery disease	6.7e-05	0.000479	CcSEcCtD
Dihydroergotamine—Headache—Lovastatin—coronary artery disease	6.69e-05	0.000479	CcSEcCtD
Dihydroergotamine—Pruritus—Valsartan—coronary artery disease	6.67e-05	0.000477	CcSEcCtD
Dihydroergotamine—Dry mouth—Ramipril—coronary artery disease	6.67e-05	0.000477	CcSEcCtD
Dihydroergotamine—Arthralgia—Timolol—coronary artery disease	6.67e-05	0.000477	CcSEcCtD
Dihydroergotamine—Myalgia—Timolol—coronary artery disease	6.67e-05	0.000477	CcSEcCtD
Dihydroergotamine—Vomiting—Ezetimibe—coronary artery disease	6.66e-05	0.000476	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Pravastatin—coronary artery disease	6.65e-05	0.000476	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Perindopril—coronary artery disease	6.65e-05	0.000476	CcSEcCtD
Dihydroergotamine—Anxiety—Timolol—coronary artery disease	6.65e-05	0.000476	CcSEcCtD
Dihydroergotamine—Pruritus—Olmesartan—coronary artery disease	6.64e-05	0.000475	CcSEcCtD
Dihydroergotamine—Decreased appetite—Losartan—coronary artery disease	6.63e-05	0.000474	CcSEcCtD
Dihydroergotamine—Body temperature increased—Captopril—coronary artery disease	6.62e-05	0.000474	CcSEcCtD
Dihydroergotamine—Abdominal pain—Captopril—coronary artery disease	6.62e-05	0.000474	CcSEcCtD
Dihydroergotamine—Dizziness—Simvastatin—coronary artery disease	6.6e-05	0.000472	CcSEcCtD
Dihydroergotamine—Rash—Ezetimibe—coronary artery disease	6.6e-05	0.000472	CcSEcCtD
Dihydroergotamine—Dermatitis—Ezetimibe—coronary artery disease	6.6e-05	0.000472	CcSEcCtD
Dihydroergotamine—Confusional state—Ramipril—coronary artery disease	6.59e-05	0.000472	CcSEcCtD
Dihydroergotamine—Discomfort—Timolol—coronary artery disease	6.59e-05	0.000471	CcSEcCtD
Dihydroergotamine—Asthenia—Niacin—coronary artery disease	6.58e-05	0.000471	CcSEcCtD
Dihydroergotamine—Fatigue—Losartan—coronary artery disease	6.58e-05	0.00047	CcSEcCtD
Dihydroergotamine—Headache—Ezetimibe—coronary artery disease	6.56e-05	0.000469	CcSEcCtD
Dihydroergotamine—Malaise—Lisinopril—coronary artery disease	6.55e-05	0.000469	CcSEcCtD
Dihydroergotamine—Oedema—Ramipril—coronary artery disease	6.54e-05	0.000468	CcSEcCtD
Dihydroergotamine—Vertigo—Lisinopril—coronary artery disease	6.53e-05	0.000467	CcSEcCtD
Dihydroergotamine—Dry mouth—Timolol—coronary artery disease	6.52e-05	0.000467	CcSEcCtD
Dihydroergotamine—Pain—Losartan—coronary artery disease	6.52e-05	0.000467	CcSEcCtD
Dihydroergotamine—Vomiting—Eplerenone—coronary artery disease	6.52e-05	0.000466	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Furosemide—coronary artery disease	6.51e-05	0.000466	CcSEcCtD
Dihydroergotamine—Nausea—Fenofibrate—coronary artery disease	6.49e-05	0.000465	CcSEcCtD
Dihydroergotamine—Pruritus—Niacin—coronary artery disease	6.49e-05	0.000464	CcSEcCtD
Dihydroergotamine—Asthenia—Pravastatin—coronary artery disease	6.48e-05	0.000463	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Furosemide—coronary artery disease	6.46e-05	0.000462	CcSEcCtD
Dihydroergotamine—Rash—Eplerenone—coronary artery disease	6.46e-05	0.000462	CcSEcCtD
Dihydroergotamine—Urticaria—Perindopril—coronary artery disease	6.46e-05	0.000462	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Trandolapril—coronary artery disease	6.46e-05	0.000462	CcSEcCtD
Dihydroergotamine—Dermatitis—Eplerenone—coronary artery disease	6.46e-05	0.000462	CcSEcCtD
Dihydroergotamine—Diarrhoea—Valsartan—coronary artery disease	6.45e-05	0.000462	CcSEcCtD
Dihydroergotamine—Confusional state—Timolol—coronary artery disease	6.45e-05	0.000461	CcSEcCtD
Dihydroergotamine—Shock—Ramipril—coronary artery disease	6.43e-05	0.00046	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Enalapril—coronary artery disease	6.43e-05	0.00046	CcSEcCtD
Dihydroergotamine—Abdominal pain—Perindopril—coronary artery disease	6.43e-05	0.00046	CcSEcCtD
Dihydroergotamine—Body temperature increased—Perindopril—coronary artery disease	6.43e-05	0.00046	CcSEcCtD
Dihydroergotamine—Palpitations—Lisinopril—coronary artery disease	6.42e-05	0.000459	CcSEcCtD
Dihydroergotamine—Diarrhoea—Olmesartan—coronary artery disease	6.42e-05	0.000459	CcSEcCtD
Dihydroergotamine—Headache—Eplerenone—coronary artery disease	6.42e-05	0.000459	CcSEcCtD
Dihydroergotamine—Oedema—Timolol—coronary artery disease	6.39e-05	0.000457	CcSEcCtD
Dihydroergotamine—Pruritus—Pravastatin—coronary artery disease	6.39e-05	0.000457	CcSEcCtD
Dihydroergotamine—Nausea—Clopidogrel—coronary artery disease	6.38e-05	0.000457	CcSEcCtD
Dihydroergotamine—Tachycardia—Ramipril—coronary artery disease	6.38e-05	0.000457	CcSEcCtD
Dihydroergotamine—Vomiting—Simvastatin—coronary artery disease	6.35e-05	0.000454	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Telmisartan—coronary artery disease	6.35e-05	0.000454	CcSEcCtD
Dihydroergotamine—Nausea—Lovastatin—coronary artery disease	6.34e-05	0.000454	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Ramipril—coronary artery disease	6.32e-05	0.000452	CcSEcCtD
Dihydroergotamine—Rash—Simvastatin—coronary artery disease	6.3e-05	0.00045	CcSEcCtD
Dihydroergotamine—Dermatitis—Simvastatin—coronary artery disease	6.29e-05	0.00045	CcSEcCtD
Dihydroergotamine—Asthenia—Trandolapril—coronary artery disease	6.29e-05	0.00045	CcSEcCtD
Dihydroergotamine—Shock—Timolol—coronary artery disease	6.29e-05	0.00045	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Losartan—coronary artery disease	6.29e-05	0.00045	CcSEcCtD
Dihydroergotamine—Urticaria—Furosemide—coronary artery disease	6.28e-05	0.000449	CcSEcCtD
Dihydroergotamine—Diarrhoea—Niacin—coronary artery disease	6.27e-05	0.000449	CcSEcCtD
Dihydroergotamine—Asthenia—Enalapril—coronary artery disease	6.27e-05	0.000448	CcSEcCtD
Dihydroergotamine—Headache—Simvastatin—coronary artery disease	6.26e-05	0.000448	CcSEcCtD
Dihydroergotamine—Abdominal pain—Furosemide—coronary artery disease	6.25e-05	0.000447	CcSEcCtD
Dihydroergotamine—Body temperature increased—Furosemide—coronary artery disease	6.25e-05	0.000447	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Losartan—coronary artery disease	6.24e-05	0.000446	CcSEcCtD
Dihydroergotamine—Dizziness—Valsartan—coronary artery disease	6.24e-05	0.000446	CcSEcCtD
Dihydroergotamine—Anorexia—Ramipril—coronary artery disease	6.23e-05	0.000446	CcSEcCtD
Dihydroergotamine—Nausea—Ezetimibe—coronary artery disease	6.22e-05	0.000445	CcSEcCtD
Dihydroergotamine—Dizziness—Olmesartan—coronary artery disease	6.21e-05	0.000444	CcSEcCtD
Dihydroergotamine—Pruritus—Trandolapril—coronary artery disease	6.2e-05	0.000444	CcSEcCtD
Dihydroergotamine—Arthralgia—Lisinopril—coronary artery disease	6.19e-05	0.000443	CcSEcCtD
Dihydroergotamine—Myalgia—Lisinopril—coronary artery disease	6.19e-05	0.000443	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Timolol—coronary artery disease	6.18e-05	0.000442	CcSEcCtD
Dihydroergotamine—Asthenia—Telmisartan—coronary artery disease	6.18e-05	0.000442	CcSEcCtD
Dihydroergotamine—Pruritus—Enalapril—coronary artery disease	6.18e-05	0.000442	CcSEcCtD
Dihydroergotamine—Diarrhoea—Pravastatin—coronary artery disease	6.18e-05	0.000442	CcSEcCtD
Dihydroergotamine—Anxiety—Lisinopril—coronary artery disease	6.17e-05	0.000441	CcSEcCtD
Dihydroergotamine—Discomfort—Lisinopril—coronary artery disease	6.11e-05	0.000437	CcSEcCtD
Dihydroergotamine—Hypotension—Ramipril—coronary artery disease	6.11e-05	0.000437	CcSEcCtD
Dihydroergotamine—Anorexia—Timolol—coronary artery disease	6.09e-05	0.000436	CcSEcCtD
Dihydroergotamine—Pruritus—Telmisartan—coronary artery disease	6.09e-05	0.000436	CcSEcCtD
Dihydroergotamine—Nausea—Eplerenone—coronary artery disease	6.09e-05	0.000436	CcSEcCtD
Dihydroergotamine—Dizziness—Niacin—coronary artery disease	6.06e-05	0.000434	CcSEcCtD
Dihydroergotamine—Urticaria—Losartan—coronary artery disease	6.06e-05	0.000433	CcSEcCtD
Dihydroergotamine—Dry mouth—Lisinopril—coronary artery disease	6.05e-05	0.000433	CcSEcCtD
Dihydroergotamine—Body temperature increased—Losartan—coronary artery disease	6.03e-05	0.000431	CcSEcCtD
Dihydroergotamine—Abdominal pain—Losartan—coronary artery disease	6.03e-05	0.000431	CcSEcCtD
Dihydroergotamine—Asthenia—Captopril—coronary artery disease	6.01e-05	0.00043	CcSEcCtD
Dihydroergotamine—Diarrhoea—Trandolapril—coronary artery disease	6e-05	0.000429	CcSEcCtD
Dihydroergotamine—Vomiting—Valsartan—coronary artery disease	6e-05	0.000429	CcSEcCtD
Dihydroergotamine—Confusional state—Lisinopril—coronary artery disease	5.98e-05	0.000428	CcSEcCtD
Dihydroergotamine—Diarrhoea—Enalapril—coronary artery disease	5.97e-05	0.000427	CcSEcCtD
Dihydroergotamine—Hypotension—Timolol—coronary artery disease	5.97e-05	0.000427	CcSEcCtD
Dihydroergotamine—Dizziness—Pravastatin—coronary artery disease	5.97e-05	0.000427	CcSEcCtD
Dihydroergotamine—Vomiting—Olmesartan—coronary artery disease	5.97e-05	0.000427	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Ramipril—coronary artery disease	5.96e-05	0.000426	CcSEcCtD
Dihydroergotamine—Rash—Valsartan—coronary artery disease	5.95e-05	0.000425	CcSEcCtD
Dihydroergotamine—Dermatitis—Valsartan—coronary artery disease	5.94e-05	0.000425	CcSEcCtD
Dihydroergotamine—Nausea—Simvastatin—coronary artery disease	5.93e-05	0.000424	CcSEcCtD
Dihydroergotamine—Oedema—Lisinopril—coronary artery disease	5.93e-05	0.000424	CcSEcCtD
Dihydroergotamine—Pruritus—Captopril—coronary artery disease	5.93e-05	0.000424	CcSEcCtD
Dihydroergotamine—Rash—Olmesartan—coronary artery disease	5.92e-05	0.000423	CcSEcCtD
Dihydroergotamine—Insomnia—Ramipril—coronary artery disease	5.92e-05	0.000423	CcSEcCtD
Dihydroergotamine—Dermatitis—Olmesartan—coronary artery disease	5.91e-05	0.000423	CcSEcCtD
Dihydroergotamine—Headache—Valsartan—coronary artery disease	5.91e-05	0.000423	CcSEcCtD
Dihydroergotamine—Diarrhoea—Telmisartan—coronary artery disease	5.89e-05	0.000422	CcSEcCtD
Dihydroergotamine—Headache—Olmesartan—coronary artery disease	5.88e-05	0.000421	CcSEcCtD
Dihydroergotamine—Paraesthesia—Ramipril—coronary artery disease	5.87e-05	0.00042	CcSEcCtD
Dihydroergotamine—Shock—Lisinopril—coronary artery disease	5.84e-05	0.000417	CcSEcCtD
Dihydroergotamine—Asthenia—Perindopril—coronary artery disease	5.83e-05	0.000417	CcSEcCtD
Dihydroergotamine—Dyspnoea—Ramipril—coronary artery disease	5.83e-05	0.000417	CcSEcCtD
Dihydroergotamine—Vomiting—Niacin—coronary artery disease	5.83e-05	0.000417	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Timolol—coronary artery disease	5.82e-05	0.000417	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Furosemide—coronary artery disease	5.82e-05	0.000417	CcSEcCtD
Dihydroergotamine—Somnolence—Ramipril—coronary artery disease	5.81e-05	0.000416	CcSEcCtD
Dihydroergotamine—Dizziness—Trandolapril—coronary artery disease	5.8e-05	0.000415	CcSEcCtD
Dihydroergotamine—Tachycardia—Lisinopril—coronary artery disease	5.79e-05	0.000414	CcSEcCtD
Dihydroergotamine—Insomnia—Timolol—coronary artery disease	5.78e-05	0.000414	CcSEcCtD
Dihydroergotamine—Rash—Niacin—coronary artery disease	5.78e-05	0.000414	CcSEcCtD
Dihydroergotamine—Dermatitis—Niacin—coronary artery disease	5.78e-05	0.000413	CcSEcCtD
Dihydroergotamine—Dizziness—Enalapril—coronary artery disease	5.77e-05	0.000413	CcSEcCtD
Dihydroergotamine—Dyspepsia—Ramipril—coronary artery disease	5.76e-05	0.000412	CcSEcCtD
Dihydroergotamine—Pruritus—Perindopril—coronary artery disease	5.75e-05	0.000412	CcSEcCtD
Dihydroergotamine—Headache—Niacin—coronary artery disease	5.74e-05	0.000411	CcSEcCtD
Dihydroergotamine—Paraesthesia—Timolol—coronary artery disease	5.74e-05	0.000411	CcSEcCtD
Dihydroergotamine—Vomiting—Pravastatin—coronary artery disease	5.74e-05	0.000411	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Lisinopril—coronary artery disease	5.73e-05	0.00041	CcSEcCtD
Dihydroergotamine—Diarrhoea—Captopril—coronary artery disease	5.73e-05	0.00041	CcSEcCtD
Dihydroergotamine—Dyspnoea—Timolol—coronary artery disease	5.7e-05	0.000408	CcSEcCtD
Dihydroergotamine—Dizziness—Telmisartan—coronary artery disease	5.7e-05	0.000407	CcSEcCtD
Dihydroergotamine—Rash—Pravastatin—coronary artery disease	5.69e-05	0.000407	CcSEcCtD
Dihydroergotamine—Dermatitis—Pravastatin—coronary artery disease	5.69e-05	0.000407	CcSEcCtD
Dihydroergotamine—Decreased appetite—Ramipril—coronary artery disease	5.69e-05	0.000407	CcSEcCtD
Dihydroergotamine—Somnolence—Timolol—coronary artery disease	5.68e-05	0.000407	CcSEcCtD
Dihydroergotamine—Asthenia—Furosemide—coronary artery disease	5.67e-05	0.000406	CcSEcCtD
Dihydroergotamine—Headache—Pravastatin—coronary artery disease	5.66e-05	0.000405	CcSEcCtD
Dihydroergotamine—Anorexia—Lisinopril—coronary artery disease	5.65e-05	0.000404	CcSEcCtD
Dihydroergotamine—Fatigue—Ramipril—coronary artery disease	5.64e-05	0.000403	CcSEcCtD
Dihydroergotamine—Dyspepsia—Timolol—coronary artery disease	5.63e-05	0.000403	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Losartan—coronary artery disease	5.62e-05	0.000402	CcSEcCtD
Dihydroergotamine—Nausea—Valsartan—coronary artery disease	5.6e-05	0.000401	CcSEcCtD
Dihydroergotamine—Pruritus—Furosemide—coronary artery disease	5.59e-05	0.0004	CcSEcCtD
Dihydroergotamine—Nausea—Olmesartan—coronary artery disease	5.57e-05	0.000399	CcSEcCtD
Dihydroergotamine—Vomiting—Trandolapril—coronary artery disease	5.57e-05	0.000399	CcSEcCtD
Dihydroergotamine—Diarrhoea—Perindopril—coronary artery disease	5.56e-05	0.000398	CcSEcCtD
Dihydroergotamine—Decreased appetite—Timolol—coronary artery disease	5.56e-05	0.000398	CcSEcCtD
Dihydroergotamine—Vomiting—Enalapril—coronary artery disease	5.55e-05	0.000397	CcSEcCtD
Dihydroergotamine—Hypotension—Lisinopril—coronary artery disease	5.54e-05	0.000397	CcSEcCtD
Dihydroergotamine—Dizziness—Captopril—coronary artery disease	5.54e-05	0.000396	CcSEcCtD
Dihydroergotamine—Rash—Trandolapril—coronary artery disease	5.53e-05	0.000395	CcSEcCtD
Dihydroergotamine—Dermatitis—Trandolapril—coronary artery disease	5.52e-05	0.000395	CcSEcCtD
Dihydroergotamine—Fatigue—Timolol—coronary artery disease	5.51e-05	0.000394	CcSEcCtD
Dihydroergotamine—Rash—Enalapril—coronary artery disease	5.51e-05	0.000394	CcSEcCtD
Dihydroergotamine—Dermatitis—Enalapril—coronary artery disease	5.5e-05	0.000394	CcSEcCtD
Dihydroergotamine—Headache—Trandolapril—coronary artery disease	5.49e-05	0.000393	CcSEcCtD
Dihydroergotamine—Vomiting—Telmisartan—coronary artery disease	5.48e-05	0.000392	CcSEcCtD
Dihydroergotamine—Asthenia—Losartan—coronary artery disease	5.47e-05	0.000392	CcSEcCtD
Dihydroergotamine—Headache—Enalapril—coronary artery disease	5.47e-05	0.000391	CcSEcCtD
Dihydroergotamine—Pain—Timolol—coronary artery disease	5.47e-05	0.000391	CcSEcCtD
Dihydroergotamine—Nausea—Niacin—coronary artery disease	5.45e-05	0.00039	CcSEcCtD
Dihydroergotamine—Rash—Telmisartan—coronary artery disease	5.43e-05	0.000389	CcSEcCtD
Dihydroergotamine—Dermatitis—Telmisartan—coronary artery disease	5.43e-05	0.000388	CcSEcCtD
Dihydroergotamine—Diarrhoea—Furosemide—coronary artery disease	5.41e-05	0.000387	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Lisinopril—coronary artery disease	5.4e-05	0.000387	CcSEcCtD
Dihydroergotamine—Pruritus—Losartan—coronary artery disease	5.4e-05	0.000386	CcSEcCtD
Dihydroergotamine—Headache—Telmisartan—coronary artery disease	5.4e-05	0.000386	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Ramipril—coronary artery disease	5.39e-05	0.000386	CcSEcCtD
Dihydroergotamine—Dizziness—Perindopril—coronary artery disease	5.38e-05	0.000385	CcSEcCtD
Dihydroergotamine—Insomnia—Lisinopril—coronary artery disease	5.36e-05	0.000384	CcSEcCtD
Dihydroergotamine—Nausea—Pravastatin—coronary artery disease	5.36e-05	0.000384	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Ramipril—coronary artery disease	5.35e-05	0.000383	CcSEcCtD
Dihydroergotamine—Paraesthesia—Lisinopril—coronary artery disease	5.33e-05	0.000381	CcSEcCtD
Dihydroergotamine—Vomiting—Captopril—coronary artery disease	5.33e-05	0.000381	CcSEcCtD
Dihydroergotamine—Dyspnoea—Lisinopril—coronary artery disease	5.29e-05	0.000378	CcSEcCtD
Dihydroergotamine—Rash—Captopril—coronary artery disease	5.28e-05	0.000378	CcSEcCtD
Dihydroergotamine—Dermatitis—Captopril—coronary artery disease	5.28e-05	0.000377	CcSEcCtD
Dihydroergotamine—Somnolence—Lisinopril—coronary artery disease	5.27e-05	0.000377	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Timolol—coronary artery disease	5.27e-05	0.000377	CcSEcCtD
Dihydroergotamine—Headache—Captopril—coronary artery disease	5.25e-05	0.000375	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Timolol—coronary artery disease	5.23e-05	0.000374	CcSEcCtD
Dihydroergotamine—Dizziness—Furosemide—coronary artery disease	5.23e-05	0.000374	CcSEcCtD
Dihydroergotamine—Dyspepsia—Lisinopril—coronary artery disease	5.22e-05	0.000374	CcSEcCtD
Dihydroergotamine—Diarrhoea—Losartan—coronary artery disease	5.22e-05	0.000373	CcSEcCtD
Dihydroergotamine—Nausea—Trandolapril—coronary artery disease	5.21e-05	0.000373	CcSEcCtD
Dihydroergotamine—Urticaria—Ramipril—coronary artery disease	5.2e-05	0.000372	CcSEcCtD
Dihydroergotamine—Nausea—Enalapril—coronary artery disease	5.19e-05	0.000371	CcSEcCtD
Dihydroergotamine—Vomiting—Perindopril—coronary artery disease	5.17e-05	0.00037	CcSEcCtD
Dihydroergotamine—Abdominal pain—Ramipril—coronary artery disease	5.17e-05	0.00037	CcSEcCtD
Dihydroergotamine—Body temperature increased—Ramipril—coronary artery disease	5.17e-05	0.00037	CcSEcCtD
Dihydroergotamine—Decreased appetite—Lisinopril—coronary artery disease	5.16e-05	0.000369	CcSEcCtD
Dihydroergotamine—Rash—Perindopril—coronary artery disease	5.13e-05	0.000367	CcSEcCtD
Dihydroergotamine—Dermatitis—Perindopril—coronary artery disease	5.12e-05	0.000366	CcSEcCtD
Dihydroergotamine—Nausea—Telmisartan—coronary artery disease	5.12e-05	0.000366	CcSEcCtD
Dihydroergotamine—Fatigue—Lisinopril—coronary artery disease	5.11e-05	0.000366	CcSEcCtD
Dihydroergotamine—Headache—Perindopril—coronary artery disease	5.09e-05	0.000364	CcSEcCtD
Dihydroergotamine—Urticaria—Timolol—coronary artery disease	5.08e-05	0.000363	CcSEcCtD
Dihydroergotamine—Pain—Lisinopril—coronary artery disease	5.07e-05	0.000363	CcSEcCtD
Dihydroergotamine—Body temperature increased—Timolol—coronary artery disease	5.05e-05	0.000362	CcSEcCtD
Dihydroergotamine—Abdominal pain—Timolol—coronary artery disease	5.05e-05	0.000362	CcSEcCtD
Dihydroergotamine—Dizziness—Losartan—coronary artery disease	5.04e-05	0.000361	CcSEcCtD
Dihydroergotamine—Vomiting—Furosemide—coronary artery disease	5.03e-05	0.00036	CcSEcCtD
Dihydroergotamine—Rash—Furosemide—coronary artery disease	4.98e-05	0.000357	CcSEcCtD
Dihydroergotamine—Dermatitis—Furosemide—coronary artery disease	4.98e-05	0.000356	CcSEcCtD
Dihydroergotamine—Nausea—Captopril—coronary artery disease	4.97e-05	0.000356	CcSEcCtD
Dihydroergotamine—Headache—Furosemide—coronary artery disease	4.95e-05	0.000354	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Lisinopril—coronary artery disease	4.89e-05	0.00035	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Lisinopril—coronary artery disease	4.85e-05	0.000347	CcSEcCtD
Dihydroergotamine—Vomiting—Losartan—coronary artery disease	4.85e-05	0.000347	CcSEcCtD
Dihydroergotamine—Nausea—Perindopril—coronary artery disease	4.83e-05	0.000346	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Ramipril—coronary artery disease	4.82e-05	0.000345	CcSEcCtD
Dihydroergotamine—Rash—Losartan—coronary artery disease	4.81e-05	0.000344	CcSEcCtD
Dihydroergotamine—Dermatitis—Losartan—coronary artery disease	4.8e-05	0.000344	CcSEcCtD
Dihydroergotamine—Headache—Losartan—coronary artery disease	4.78e-05	0.000342	CcSEcCtD
Dihydroergotamine—Urticaria—Lisinopril—coronary artery disease	4.71e-05	0.000337	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Timolol—coronary artery disease	4.71e-05	0.000337	CcSEcCtD
Dihydroergotamine—Nausea—Furosemide—coronary artery disease	4.7e-05	0.000336	CcSEcCtD
Dihydroergotamine—Asthenia—Ramipril—coronary artery disease	4.69e-05	0.000336	CcSEcCtD
Dihydroergotamine—Abdominal pain—Lisinopril—coronary artery disease	4.69e-05	0.000335	CcSEcCtD
Dihydroergotamine—Body temperature increased—Lisinopril—coronary artery disease	4.69e-05	0.000335	CcSEcCtD
Dihydroergotamine—Pruritus—Ramipril—coronary artery disease	4.63e-05	0.000331	CcSEcCtD
Dihydroergotamine—Asthenia—Timolol—coronary artery disease	4.59e-05	0.000328	CcSEcCtD
Dihydroergotamine—Nausea—Losartan—coronary artery disease	4.53e-05	0.000324	CcSEcCtD
Dihydroergotamine—Pruritus—Timolol—coronary artery disease	4.52e-05	0.000324	CcSEcCtD
Dihydroergotamine—Diarrhoea—Ramipril—coronary artery disease	4.47e-05	0.00032	CcSEcCtD
Dihydroergotamine—Diarrhoea—Timolol—coronary artery disease	4.37e-05	0.000313	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Lisinopril—coronary artery disease	4.37e-05	0.000313	CcSEcCtD
Dihydroergotamine—Dizziness—Ramipril—coronary artery disease	4.32e-05	0.000309	CcSEcCtD
Dihydroergotamine—Asthenia—Lisinopril—coronary artery disease	4.26e-05	0.000304	CcSEcCtD
Dihydroergotamine—Dizziness—Timolol—coronary artery disease	4.23e-05	0.000302	CcSEcCtD
Dihydroergotamine—Pruritus—Lisinopril—coronary artery disease	4.2e-05	0.0003	CcSEcCtD
Dihydroergotamine—Vomiting—Ramipril—coronary artery disease	4.16e-05	0.000297	CcSEcCtD
Dihydroergotamine—Rash—Ramipril—coronary artery disease	4.12e-05	0.000295	CcSEcCtD
Dihydroergotamine—Dermatitis—Ramipril—coronary artery disease	4.12e-05	0.000295	CcSEcCtD
Dihydroergotamine—Headache—Ramipril—coronary artery disease	4.1e-05	0.000293	CcSEcCtD
Dihydroergotamine—Vomiting—Timolol—coronary artery disease	4.07e-05	0.000291	CcSEcCtD
Dihydroergotamine—Diarrhoea—Lisinopril—coronary artery disease	4.06e-05	0.00029	CcSEcCtD
Dihydroergotamine—Rash—Timolol—coronary artery disease	4.03e-05	0.000288	CcSEcCtD
Dihydroergotamine—Dermatitis—Timolol—coronary artery disease	4.03e-05	0.000288	CcSEcCtD
Dihydroergotamine—Headache—Timolol—coronary artery disease	4.01e-05	0.000287	CcSEcCtD
Dihydroergotamine—Dizziness—Lisinopril—coronary artery disease	3.92e-05	0.000281	CcSEcCtD
Dihydroergotamine—Nausea—Ramipril—coronary artery disease	3.88e-05	0.000278	CcSEcCtD
Dihydroergotamine—Nausea—Timolol—coronary artery disease	3.8e-05	0.000272	CcSEcCtD
Dihydroergotamine—Vomiting—Lisinopril—coronary artery disease	3.77e-05	0.00027	CcSEcCtD
Dihydroergotamine—Rash—Lisinopril—coronary artery disease	3.74e-05	0.000268	CcSEcCtD
Dihydroergotamine—Dermatitis—Lisinopril—coronary artery disease	3.74e-05	0.000267	CcSEcCtD
Dihydroergotamine—Headache—Lisinopril—coronary artery disease	3.72e-05	0.000266	CcSEcCtD
Dihydroergotamine—Nausea—Lisinopril—coronary artery disease	3.52e-05	0.000252	CcSEcCtD
Dihydroergotamine—HTR2B—Signaling by GPCR—MAPK1—coronary artery disease	3.39e-06	4.47e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NOS3—coronary artery disease	3.39e-06	4.46e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MTHFR—coronary artery disease	3.38e-06	4.45e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HADHA—coronary artery disease	3.37e-06	4.44e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NOS3—coronary artery disease	3.36e-06	4.43e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APOE—coronary artery disease	3.35e-06	4.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—LEP—coronary artery disease	3.35e-06	4.41e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—FGF2—coronary artery disease	3.34e-06	4.39e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTA1—coronary artery disease	3.34e-06	4.39e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—APOA1—coronary artery disease	3.31e-06	4.36e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ABCA1—coronary artery disease	3.31e-06	4.35e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—LPA—coronary artery disease	3.3e-06	4.34e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—JAK2—coronary artery disease	3.29e-06	4.33e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NOS3—coronary artery disease	3.29e-06	4.33e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOB—coronary artery disease	3.29e-06	4.33e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KDR—coronary artery disease	3.28e-06	4.32e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—PIK3CA—coronary artery disease	3.27e-06	4.31e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—JAK2—coronary artery disease	3.27e-06	4.3e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CXCL8—coronary artery disease	3.26e-06	4.29e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK14—coronary artery disease	3.26e-06	4.29e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—PIK3CA—coronary artery disease	3.24e-06	4.27e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—JAK2—coronary artery disease	3.24e-06	4.27e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SERPINE1—coronary artery disease	3.24e-06	4.26e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EDN1—coronary artery disease	3.23e-06	4.26e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—PIK3CA—coronary artery disease	3.23e-06	4.25e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AGT—coronary artery disease	3.21e-06	4.23e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCL5—coronary artery disease	3.21e-06	4.23e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GOT1—coronary artery disease	3.2e-06	4.22e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GGT1—coronary artery disease	3.2e-06	4.22e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—PIK3CA—coronary artery disease	3.2e-06	4.22e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—JAK2—coronary artery disease	3.2e-06	4.21e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ESR1—coronary artery disease	3.2e-06	4.21e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PLCB3—coronary artery disease	3.19e-06	4.21e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOA5—coronary artery disease	3.16e-06	4.16e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CSF2—coronary artery disease	3.16e-06	4.16e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGF1—coronary artery disease	3.16e-06	4.16e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—F2—coronary artery disease	3.16e-06	4.16e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FN1—coronary artery disease	3.16e-06	4.16e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—APOE—coronary artery disease	3.15e-06	4.14e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6ST—coronary artery disease	3.14e-06	4.14e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—LPL—coronary artery disease	3.14e-06	4.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—PIK3CA—coronary artery disease	3.14e-06	4.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—FGF2—coronary artery disease	3.13e-06	4.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NFKBIA—coronary artery disease	3.12e-06	4.11e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—RPS6KB1—coronary artery disease	3.11e-06	4.1e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MEF2C—coronary artery disease	3.11e-06	4.1e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—APOA1—coronary artery disease	3.11e-06	4.09e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—P4HB—coronary artery disease	3.1e-06	4.08e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NOS3—coronary artery disease	3.09e-06	4.07e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PLA2G1B—coronary artery disease	3.04e-06	4.01e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ITGB3—coronary artery disease	3.03e-06	3.99e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—KIT—coronary artery disease	3.02e-06	3.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—JAK2—coronary artery disease	3e-06	3.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CXCL8—coronary artery disease	3e-06	3.96e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CXCL8—coronary artery disease	2.98e-06	3.93e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CXCL8—coronary artery disease	2.96e-06	3.9e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—PIK3CA—coronary artery disease	2.95e-06	3.88e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PPP2CA—coronary artery disease	2.94e-06	3.88e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CXCL8—coronary artery disease	2.92e-06	3.84e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—AKT1—coronary artery disease	2.9e-06	3.82e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—GSK3B—coronary artery disease	2.9e-06	3.82e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PRKCD—coronary artery disease	2.89e-06	3.81e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—AKT1—coronary artery disease	2.88e-06	3.79e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTP1—coronary artery disease	2.88e-06	3.79e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CASP3—coronary artery disease	2.88e-06	3.79e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—POMC—coronary artery disease	2.88e-06	3.79e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CREB1—coronary artery disease	2.88e-06	3.79e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—VCAN—coronary artery disease	2.87e-06	3.78e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—IL6—coronary artery disease	2.86e-06	3.76e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CASP3—coronary artery disease	2.85e-06	3.76e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARGC1A—coronary artery disease	2.85e-06	3.75e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALDOA—coronary artery disease	2.85e-06	3.75e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—HMOX1—coronary artery disease	2.84e-06	3.74e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—IL6—coronary artery disease	2.84e-06	3.73e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HTR2A—coronary artery disease	2.83e-06	3.73e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—C3—coronary artery disease	2.83e-06	3.72e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—AKT1—coronary artery disease	2.82e-06	3.71e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCL2—coronary artery disease	2.81e-06	3.7e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6R—coronary artery disease	2.8e-06	3.69e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CAT—coronary artery disease	2.8e-06	3.69e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CCND1—coronary artery disease	2.8e-06	3.69e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CASP3—coronary artery disease	2.79e-06	3.68e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CCND1—coronary artery disease	2.78e-06	3.66e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—IL6—coronary artery disease	2.78e-06	3.66e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IGF1—coronary artery disease	2.77e-06	3.64e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—DCN—coronary artery disease	2.76e-06	3.64e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—MAPK1—coronary artery disease	2.75e-06	3.62e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CXCL8—coronary artery disease	2.74e-06	3.61e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PPARG—coronary artery disease	2.74e-06	3.61e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CCND1—coronary artery disease	2.72e-06	3.58e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOB—coronary artery disease	2.72e-06	3.58e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MMP9—coronary artery disease	2.72e-06	3.58e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—POMC—coronary artery disease	2.7e-06	3.56e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MMP9—coronary artery disease	2.7e-06	3.55e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HIF1A—coronary artery disease	2.69e-06	3.55e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALDH2—coronary artery disease	2.69e-06	3.54e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AGT—coronary artery disease	2.68e-06	3.54e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—AKT1—coronary artery disease	2.67e-06	3.52e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—AKT1—coronary artery disease	2.65e-06	3.49e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GSTM1—coronary artery disease	2.64e-06	3.48e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MMP9—coronary artery disease	2.64e-06	3.48e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—AKT1—coronary artery disease	2.64e-06	3.47e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—LEP—coronary artery disease	2.63e-06	3.46e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOE—coronary artery disease	2.63e-06	3.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—PIK3CA—coronary artery disease	2.63e-06	3.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SERPINE1—coronary artery disease	2.63e-06	3.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CASP3—coronary artery disease	2.62e-06	3.46e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—LIPC—coronary artery disease	2.62e-06	3.45e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HBA1—coronary artery disease	2.62e-06	3.45e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3C2A—coronary artery disease	2.62e-06	3.45e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CYP2C19—coronary artery disease	2.62e-06	3.45e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—AKT1—coronary artery disease	2.62e-06	3.44e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—IL6—coronary artery disease	2.61e-06	3.43e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOC3—coronary artery disease	2.6e-06	3.43e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—APOA1—coronary artery disease	2.6e-06	3.42e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—LPL—coronary artery disease	2.6e-06	3.42e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—LDLR—coronary artery disease	2.59e-06	3.41e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KDR—coronary artery disease	2.58e-06	3.39e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—AKT1—coronary artery disease	2.56e-06	3.37e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK14—coronary artery disease	2.56e-06	3.37e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTT1—coronary artery disease	2.56e-06	3.37e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SLC9A1—coronary artery disease	2.56e-06	3.37e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CCND1—coronary artery disease	2.56e-06	3.36e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FGF2—coronary artery disease	2.54e-06	3.35e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GPX1—coronary artery disease	2.53e-06	3.33e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GCLC—coronary artery disease	2.53e-06	3.33e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CETP—coronary artery disease	2.53e-06	3.33e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ESR1—coronary artery disease	2.51e-06	3.31e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NOS3—coronary artery disease	2.51e-06	3.3e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SDC1—coronary artery disease	2.5e-06	3.29e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—F2—coronary artery disease	2.48e-06	3.27e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MMP9—coronary artery disease	2.48e-06	3.27e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FN1—coronary artery disease	2.48e-06	3.27e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6ST—coronary artery disease	2.47e-06	3.25e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CD36—coronary artery disease	2.47e-06	3.25e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ALB—coronary artery disease	2.46e-06	3.24e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NFKBIA—coronary artery disease	2.45e-06	3.23e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—VEGFA—coronary artery disease	2.44e-06	3.21e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—JAK2—coronary artery disease	2.44e-06	3.21e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPP2CA—coronary artery disease	2.43e-06	3.21e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—VEGFA—coronary artery disease	2.42e-06	3.19e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—AKT1—coronary artery disease	2.41e-06	3.17e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PIK3CA—coronary artery disease	2.39e-06	3.14e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—KIT—coronary artery disease	2.37e-06	3.13e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—VEGFA—coronary artery disease	2.37e-06	3.12e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PSMA6—coronary artery disease	2.36e-06	3.11e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PSMB5—coronary artery disease	2.36e-06	3.11e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—NOS3—coronary artery disease	2.36e-06	3.1e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MTHFR—coronary artery disease	2.34e-06	3.08e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CTGF—coronary artery disease	2.31e-06	3.04e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GOT2—coronary artery disease	2.29e-06	3.01e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HMGCR—coronary artery disease	2.29e-06	3.01e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GSK3B—coronary artery disease	2.28e-06	3e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—POMC—coronary artery disease	2.26e-06	2.98e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CREB1—coronary artery disease	2.26e-06	2.98e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TGFB1—coronary artery disease	2.24e-06	2.95e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—VEGFA—coronary artery disease	2.23e-06	2.93e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CXCL8—coronary artery disease	2.22e-06	2.93e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TGFB1—coronary artery disease	2.22e-06	2.93e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AGT—coronary artery disease	2.22e-06	2.92e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCL2—coronary artery disease	2.21e-06	2.91e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6R—coronary artery disease	2.2e-06	2.9e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MAPK1—coronary artery disease	2.2e-06	2.89e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MAPK1—coronary artery disease	2.18e-06	2.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TGFB1—coronary artery disease	2.18e-06	2.87e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOE—coronary artery disease	2.18e-06	2.86e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IGF1—coronary artery disease	2.17e-06	2.86e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—MAPK1—coronary artery disease	2.16e-06	2.85e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTGS2—coronary artery disease	2.16e-06	2.84e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—APOA1—coronary artery disease	2.15e-06	2.83e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—AKT1—coronary artery disease	2.15e-06	2.83e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MAPK1—coronary artery disease	2.13e-06	2.81e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CASP3—coronary artery disease	2.13e-06	2.8e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—IL6—coronary artery disease	2.11e-06	2.78e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PLCB1—coronary artery disease	2.1e-06	2.77e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CCND1—coronary artery disease	2.07e-06	2.73e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—PIK3CA—coronary artery disease	2.07e-06	2.72e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SERPINE1—coronary artery disease	2.06e-06	2.72e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TGFB1—coronary artery disease	2.04e-06	2.69e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ABCA1—coronary artery disease	2.04e-06	2.68e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MMP9—coronary artery disease	2.01e-06	2.65e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MAPK1—coronary artery disease	2e-06	2.64e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGF2—coronary artery disease	2e-06	2.63e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GGT1—coronary artery disease	1.97e-06	2.6e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GOT1—coronary artery disease	1.97e-06	2.6e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOS3—coronary artery disease	1.97e-06	2.59e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—AKT1—coronary artery disease	1.95e-06	2.57e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—JAK2—coronary artery disease	1.92e-06	2.52e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PIK3CA—coronary artery disease	1.91e-06	2.51e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PPARG—coronary artery disease	1.89e-06	2.49e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PIK3CA—coronary artery disease	1.89e-06	2.49e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PIK3CA—coronary artery disease	1.88e-06	2.47e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—POMC—coronary artery disease	1.87e-06	2.46e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PIK3CA—coronary artery disease	1.85e-06	2.44e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—VEGFA—coronary artery disease	1.81e-06	2.38e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTP1—coronary artery disease	1.77e-06	2.33e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARGC1A—coronary artery disease	1.76e-06	2.31e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—HMOX1—coronary artery disease	1.75e-06	2.3e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CXCL8—coronary artery disease	1.75e-06	2.3e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PIK3CA—coronary artery disease	1.74e-06	2.29e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CAT—coronary artery disease	1.72e-06	2.27e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—ALB—coronary artery disease	1.7e-06	2.24e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—AKT1—coronary artery disease	1.69e-06	2.22e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IL6—coronary artery disease	1.69e-06	2.22e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IL6—coronary artery disease	1.67e-06	2.21e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOB—coronary artery disease	1.67e-06	2.2e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CASP3—coronary artery disease	1.67e-06	2.2e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—IL6—coronary artery disease	1.66e-06	2.19e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TGFB1—coronary artery disease	1.66e-06	2.18e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IL6—coronary artery disease	1.64e-06	2.16e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—NOS3—coronary artery disease	1.63e-06	2.15e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GSTM1—coronary artery disease	1.63e-06	2.14e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CCND1—coronary artery disease	1.63e-06	2.14e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MAPK1—coronary artery disease	1.63e-06	2.14e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—LPL—coronary artery disease	1.6e-06	2.11e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MMP9—coronary artery disease	1.58e-06	2.08e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GPX1—coronary artery disease	1.56e-06	2.05e-05	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AKT1—coronary artery disease	1.56e-06	2.05e-05	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AKT1—coronary artery disease	1.55e-06	2.03e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IL6—coronary artery disease	1.54e-06	2.03e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—AKT1—coronary artery disease	1.53e-06	2.02e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CD36—coronary artery disease	1.52e-06	2e-05	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKT1—coronary artery disease	1.51e-06	1.99e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPP2CA—coronary artery disease	1.5e-06	1.98e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTGS2—coronary artery disease	1.49e-06	1.96e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MTHFR—coronary artery disease	1.44e-06	1.9e-05	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKT1—coronary artery disease	1.42e-06	1.87e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—VEGFA—coronary artery disease	1.42e-06	1.87e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PIK3CA—coronary artery disease	1.41e-06	1.86e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AGT—coronary artery disease	1.37e-06	1.8e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOE—coronary artery disease	1.34e-06	1.76e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PIK3CA—coronary artery disease	1.33e-06	1.75e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—APOA1—coronary artery disease	1.32e-06	1.74e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TGFB1—coronary artery disease	1.3e-06	1.72e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MAPK1—coronary artery disease	1.28e-06	1.68e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IL6—coronary artery disease	1.25e-06	1.65e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PPARG—coronary artery disease	1.17e-06	1.54e-05	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKT1—coronary artery disease	1.15e-06	1.52e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—POMC—coronary artery disease	1.15e-06	1.52e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PIK3CA—coronary artery disease	1.11e-06	1.46e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—AKT1—coronary artery disease	1.08e-06	1.43e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ALB—coronary artery disease	1.05e-06	1.38e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—NOS3—coronary artery disease	1e-06	1.32e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IL6—coronary artery disease	9.82e-07	1.29e-05	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS2—coronary artery disease	9.18e-07	1.21e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PIK3CA—coronary artery disease	9.17e-07	1.21e-05	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKT1—coronary artery disease	9.06e-07	1.19e-05	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—AKT1—coronary artery disease	7.49e-07	9.86e-06	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PIK3CA—coronary artery disease	5.65e-07	7.44e-06	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—AKT1—coronary artery disease	4.62e-07	6.08e-06	CbGpPWpGaD
